Contemporary treatment patterns in plaque psoriasis and psoriatic arthritis

被引:1
|
作者
Jenerowicz, Dorota [1 ]
Kaznowska, Justyna [1 ]
Bartkiewicz, Pawel [1 ]
Sadowska-Przytocka, Anna [1 ]
Szymkowiak, Marcin [2 ]
Adamski, Zygmunt [1 ]
Czarnecka-Operacz, Magdalena [1 ]
机构
[1] Poznan Univ Med Sci, Dept Dermatol, 49 Przybyszewskiego St, Poznan, Poland
[2] Poznan Univ Econ & Business, Dept Stat, Poznan, Poland
来源
POSTEPY DERMATOLOGII I ALERGOLOGII | 2021年 / 38卷 / 01期
关键词
treatment; psoriasis; dermatologist; VULGARIS GUIDELINES; METHOTREXATE; MANAGEMENT; BIOLOGICS;
D O I
10.5114/ada.2019.91502
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Introduction: Psoriasis is a chronic inflammatory skin disease affecting about 2% of the general population. Although there are many treatment options, and new medications have been introduced, the disease is considered not curable, and it may seriously affect patients' quality of life. Aim: The authors present contemporary treatment patterns used by dermatologists in Poland to manage plaque psoriasis and psoriatic arthritis, particularly regarding systemic treatment. The authors also aimed to analyse how these treatment patterns are influenced by the guidelines of the Polish Dermatological Society. Material and methods: The author's questionnaire, consisting of 13 questions was used. It included demographic and professional characteristics of questioned dermatologists, as well as the assessment of the attitudes towards management of plaque psoriasis and psoriatic arthritis. Results: A total of 132 dermatologists completed the questionnaire. Most of the specialists worked in out-patient clinics and private practices. The most commonly used topicals for psoriasis included: glucocorticosteroids, a combination of glucocorticosteroid and vitamin D analogue and salicylic acid. Regarding the treatment of psoriatic arthritis, most of the specialists declared using systemic therapy and a combination of systemic therapy and phototherapy. The majority of the respondents were particularly concerned with possible side effects or difficulties in qualifying and monitoring the patients, and less frequently on the cost of the therapy. Conclusions: Observations suggest that 60% of physicians have some reservation to initiate systemic treatment in outpatient clinics, and they admit that they lack additional training. On the other hand, it seems also that the organization of systemic treatment in psoriasis may generate these difficulties and thus necessitate additional effort. Another factor could be the budget - not only regarding healthcare professionals, but also the patient, sometimes financing various investigations from private resources.
引用
收藏
页码:80 / 84
页数:5
相关论文
共 50 条
  • [1] Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis
    Esposito, Maria
    Carubbi, Francesco
    Giunta, Alessandro
    Alunno, Alessia
    Giacomelli, Roberto
    Fargnoli, Maria Concetta
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (02) : 119 - 128
  • [2] Ustekinumab: A Review in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
    Zaghi, Daniel
    Krueger, Gerald G.
    Duffin, Kristina Callis
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (02) : 160 - 167
  • [3] Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis
    Saraceno, Rosita
    Bavetta, Mauro
    Zangrilli, Arianna
    Chiricozzi, Andrea
    Potenza, Concetta
    Chimenti, Sergio
    Chimenti, Maria Sole
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (09) : 1325 - 1334
  • [4] TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY PSORIATIC ARTHRITIS STATUS
    Feldman, S. R.
    Zhang, J.
    Martinez, D.
    Lopez-Gonzalez, L.
    Marchlewicz, E.
    Shrady, G.
    Lowry, S.
    Mendelsohn, A. B.
    Zhao, Y.
    [J]. VALUE IN HEALTH, 2019, 22 : S55 - S55
  • [5] Spotlight on etanercept in plaque psoriasis and psoriatic arthritis
    Goldsmith, DR
    Wagstaff, AJ
    [J]. BIODRUGS, 2005, 19 (06) : 401 - 403
  • [6] Spotlight on Etanercept in Plaque Psoriasis and Psoriatic Arthritis
    David R. Goldsmith
    Antona J. Wagstaff
    [J]. BioDrugs, 2005, 19 : 401 - 403
  • [7] Risk of psoriatic arthritis in chronic plaque psoriasis
    Thorley, Jennifer
    [J]. LANCET RHEUMATOLOGY, 2021, 3 (08): : E550 - E550
  • [8] Treatment of Psoriasis and Psoriatic Arthritis
    Papoutsaki, Marina
    Costanzo, Antonio
    [J]. BIODRUGS, 2013, 27 : 3 - 12
  • [9] Psoriasis and Psoriatic Arthritis Treatment
    Menter, Alan
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (08): : S225 - S237
  • [10] Treatment of psoriasis and psoriatic arthritis
    Papoutsaki M.
    Costanzo A.
    [J]. BioDrugs, 2013, 27 (Suppl 1) : 3 - 12